The assistant professor of neurology at Mayo Clinic detailed his presentation at ACTRIMS 2021 Forum on the rising prevalence of autoimmune encephalitis.
"Over time, what we’ve seen is just an exponential growth in the number of these antibodies, which has been a chain reaction of sorts.”
At the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2021, February 25–27, a group of presenters focused on the spectrum of other non-MS inflammatory central nervous system (CNS) diseases. Among them was Divyanshu Dubey, MBBS, who discussed the increasing incidence of autoimmune encephalitis and the lack of recently updated data regarding its prevalence.
Dubey, an assistant professor of neurology at Mayo Clinic, wrote that recognition of clinical and paraclinical features associated with autoimmune encephalitis is becoming critical for inpatient and outpatient neurology practice, even as the condition remains treatable. He also stressed that understanding the diagnostic potential of autoantibody detection assays can help clinicians optimize their autoimmune panels.
In an interview with NeurologyLive, Dubey discussed why he decided to speak on this topic, and the reasons for the growing amount of research within this field in recent years.
For more coverage of ACTRIMS 2021, click here.